

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 NOV 21 CAS patent coverage to include exemplified prophetic
substances identified in English-, French-, German-,
and Japanese-language basic patents from 2004-present
NEWS 3 NOV 26 MARPAT enhanced with FSORT command
NEWS 4 NOV 26 CHEMSAFE now available on STN Easy
NEWS 5 NOV 26 Two new SET commands increase convenience of STN
searching
NEWS 6 DEC 01 ChemPort single article sales feature unavailable
NEWS 7 DEC 12 GBFULL now offers single source for full-text
coverage of complete UK patent families
NEWS 8 DEC 17 Fifty-one pharmaceutical ingredients added to PS
NEWS 9 JAN 06 The retention policy for unread STNmail messages
will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
Classification Data
NEWS 11 FEB 02 Simultaneous left and right truncation (SLART) added
for CERAB, COMPUAB, ELCOM, and SOLIDSTATEM
NEWS 12 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 14:55:22 ON 04 FEB 2009

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 14:55:31 ON 04 FEB 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 FEB 2009 HIGHEST RN 1100396-01-7
DICTIONARY FILE UPDATES: 3 FEB 2009 HIGHEST RN 1100396-01-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10588049.str



chain nodes :
9 22 23 37 38 40 41

```

ring nodes :
1  2  3  4  5  6  7  8  10 11 12 13 14 15 16 17 18 19 20 21 24 25 26
27 28 29 31 32 33 34 35 36 39
chain bonds :
5-22 6-9 9-10 9-11 22-23 23-24 31-37 36-38 39-40 39-41
ring bonds :
1-2 1-6 1-8 2-3 3-4 4-5 4-7 5-6 7-8 10-17 10-21 11-12 11-16 12-13
13-14 14-15 15-16 17-18 18-19 19-20 20-21 24-25 24-29 25-26 26-27 27-28
28-29 31-32 31-36 32-33 33-34 33-39 34-35 35-36 36-39
exact/norm bonds :
1-2 1-6 1-8 2-3 3-4 4-5 4-7 5-6 5-22 7-8 22-23 31-37
exact bonds :
6-9 9-10 9-11 23-24 31-32 31-36 32-33 33-34 33-39 34-35 35-36 36-38
36-39 39-40 39-41
normalized bonds :
10-17 10-21 11-12 11-16 12-13 13-14 14-15 15-16 17-18 18-19 19-20 20-21
24-25 24-29 25-26 26-27 27-28 28-29
isolated ring systems :
containing 1 : 10 : 11 : 24 : 31 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:CLASS 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:CLASS 38:CLASS
39:Atom 40:CLASS 41:CLASS

```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 14:55:54 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS



0 ANSWERS

SEARCH TIME: 00.00.01

L2 0 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\10588049a.str



```

chain nodes :
9 22 23 37 38
ring nodes :
1 2 3 4 5 6 7 8 10 11 12 13 14 15 16 17 18 19 20 21 24 25 26
27 28 29 31 32 33 34 35 36 39
chain bonds :
5-22 6-9 9-10 9-11 22-23 23-24 31-37 36-38
ring bonds :
1-2 1-6 1-8 2-3 3-4 4-5 4-7 5-6 7-8 10-17 10-21 11-12 11-16 12-13
13-14 14-15 15-16 17-18 18-19 19-20 20-21 24-25 24-29 25-26 26-27 27-28
28-29 31-32 31-36 32-33 33-34 33-39 34-35 35-36 36-39
exact/norm bonds :
1-2 1-6 1-8 2-3 3-4 4-5 4-7 5-6 5-22 7-8 22-23 31-37
exact bonds :
6-9 9-10 9-11 23-24 31-32 31-36 32-33 33-34 33-39 34-35 35-36 36-38
36-39
normalized bonds :
10-17 10-21 11-12 11-16 12-13 13-14 14-15 15-16 17-18 18-19 19-20 20-21
24-25 24-29 25-26 26-27 27-28 28-29
isolated ring systems :
containing 1 : 10 : 11 : 24 : 31 :
```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:CLASS 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:CLASS 38:CLASS
39:Atom
```

L3 STRUCTURE UPLOADED

=> d l3

L3 HAS NO ANSWERS

L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l3 full

FULL SEARCH INITIATED 14:57:30 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 9 TO ITERATE

100.0% PROCESSED 9 ITERATIONS


0 ANSWERS

SEARCH TIME: 00.00.01

L4 0 SEA SSS FUL L3

=>

Uploading C:\Program Files\Stnexp\Queries\10588049b.str



chain nodes :

9 22 23

ring nodes :

1 2 3 4 5 6 7 8 10 11 12 13 14 15 16 17 18 19 20 21 24 25 26
27 28 29

chain bonds :

5-22 6-9 9-10 9-11 22-23 23-24

ring bonds :

1-2 1-6 1-8 2-3 3-4 4-5 4-7 5-6 7-8 10-17 10-21 11-12 11-16 12-13
13-14 14-15 15-16 17-18 18-19 19-20 20-21 24-25 24-29 25-26 26-27 27-28
28-29

exact/norm bonds :
1-2 1-6 1-8 2-3 3-4 4-5 4-7 5-6 5-22 7-8 22-23
exact bonds :
6-9 9-10 9-11 23-24
normalized bonds :
10-17 10-21 11-12 11-16 12-13 13-14 14-15 15-16 17-18 18-19 19-20 20-21
24-25 24-29 25-26 26-27 27-28 28-29
isolated ring systems :
containing 1 : 10 : 11 : 24 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:CLASS 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom

L5 STRUCTURE UPLOADED

=> d l5

L5 HAS NO ANSWERS

L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l5 full

FULL SEARCH INITIATED 14:58:31 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1044 TO ITERATE

100.0% PROCESSED 1044 ITERATIONS


431 ANSWERS

SEARCH TIME: 00.00.01

L6 431 SEA SSS FUL L5

=>

Uploading C:\Program Files\Stnexp\Queries\10588049c.str



```

chain nodes :
9 22 23 31 32
ring nodes :
1 2 3 4 5 6 7 8 10 11 12 13 14 15 16 17 18 19 20 21 24 25 26
27 28 29
chain bonds :
5-22 6-9 9-10 9-11 22-23 23-24 25-31 31-32
ring bonds :
1-2 1-6 1-8 2-3 3-4 4-5 4-7 5-6 7-8 10-17 10-21 11-12 11-16 12-13
13-14 14-15 15-16 17-18 18-19 19-20 20-21 24-25 24-29 25-26 26-27 27-28
28-29
exact/norm bonds :
1-2 1-6 1-8 2-3 3-4 4-5 4-7 5-6 5-22 7-8 22-23 25-31
exact bonds :
6-9 9-10 9-11 23-24 31-32
normalized bonds :
10-17 10-21 11-12 11-16 12-13 13-14 14-15 15-16 17-18 18-19 19-20 20-21
24-25 24-29 25-26 26-27 27-28 28-29
isolated ring systems :
containing 1 : 10 : 11 : 24 :
```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:CLASS 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 31:CLASS 32:CLASS
```

=> d l7
L7 HAS NO ANSWERS
L7 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l7 full
FULL SEARCH INITIATED 15:02:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 500 TO ITERATE

100.0% PROCESSED 500 ITERATIONS 335 ANSWERS
SEARCH TIME: 00.00.01

L8 335 SEA SSS FUL L7

=> file casreact
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 748.32 748.54

FILE 'CASREACT' ENTERED AT 15:03:47 ON 04 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 1 Feb 2009 VOL 150 ISS 6



New CAS Information Use Policies, enter HELP USAGETERMS for details.

* CASREACT now has more than 16.5 million reactions *
* *

CASREACT contains reactions from CAS and from: ZIC/VINITI database (1974-1999) provided by InfoChem; INPI data prior to 1986; Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich; organic reactions, portions copyright 1996-2006 John Wiley & Sons, Ltd., John Wiley and Sons, Inc., Organic Reactions Inc., and Organic Syntheses Inc. Reproduced under license. All Rights Reserved.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>
Uploading C:\Program Files\Stnexp\Queries\10588049d.str



```

chain nodes :
9 22 23 31 32
ring nodes :
1 2 3 4 5 6 7 8 10 11 12 13 14 15 16 17 18 19 20 21 24 25 26
27 28 29
chain bonds :
5-22 6-9 9-10 9-11 22-23 23-24 25-31 31-32
ring bonds :
1-2 1-6 1-8 2-3 3-4 4-5 4-7 5-6 7-8 10-17 10-21 11-12 11-16 12-13
13-14 14-15 15-16 17-18 18-19 19-20 20-21 24-25 24-29 25-26 26-27 27-28
28-29
exact/norm bonds :
1-2 1-6 1-8 2-3 3-4 4-5 4-7 5-6 5-22 7-8 22-23 25-31
exact bonds :
6-9 9-10 9-11 23-24 31-32
normalized bonds :
10-17 10-21 11-12 11-16 12-13 13-14 14-15 15-16 17-18 18-19 19-20 20-21
24-25 24-29 25-26 26-27 27-28 28-29
isolated ring systems :
containing 1 : 10 : 11 : 24 :
```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:CLASS 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 31:CLASS 32:CLASS
fragments assigned product role:
containing 1
```

L9 STRUCTURE UPLOADED

=> d 19

L9 HAS NO ANSWERS

L9 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 19 full

FULL SEARCH INITIATED 15:04:09 FILE 'CASREACT'

SCREENING COMPLETE - 64 REACTIONS TO VERIFY FROM 10 DOCUMENTS

100.0% DONE 64 VERIFIED 35 HIT RXNS 7 DOCS


SEARCH TIME: 00.00.01

L10 7 SEA SSS FUL L9 (35 REACTIONS)

=> d ibib abs fhit tot


ACCESSION NUMBER: 143:230050 CASREACT
 TITLE: Process for preparation of
 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amine
 INVENTOR(S): Basford, Patricia Ann; Post, Ronald James; Smith, Julian Duncan; Taber, Geraldine Patricia
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005075473	A1	20050818	WO 2005-IB221	20050126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005210259	A1	20050818	AU 2005-210259	20050126
CA 2554360	A1	20050818	CA 2005-2554360	20050126
EP 1713801	A1	20061025	EP 2005-702373	20050126
EP 1713801	B1	20071212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1914202	A	20070214	CN 2005-80003898	20050126
BR 2005007334	A	20070703	BR 2005-7334	20050126
JP 2007519710	T	20070719	JP 2006-550351	20050126
AT 380811	T	20071215	AT 2005-702373	20050126
RU 2320659	C1	20080327	RU 2006-127969	20050126
ES 2296131	T3	20080416	ES 2005-702373	20050126
NO 2006003268	A	20060815	NO 2006-3268	20060713
IN 2006DN04065	A	20070713	IN 2006-DN4065	20060714
MX 2006008441	A	20061002	MX 2006-8441	20060726
KR 2006127966	A	20061213	KR 2006-715573	20060801
KR 812046	B1	20080310		
PRIORITY APPLN. INFO.:			US 2004-541323P	20040202
			WO 2005-IB221	20050126
OTHER SOURCE(S):		MARPAT 143:230050		
GI				




AB This invention relates to an improved process for the preparation and purification of (2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amine (I), which is useful as an antiemetic agent (no biol. testing data), and its pharmaceutically acceptable salts. In particular, the invention is directed to an improved synthesis of the monohydrate monocitrate salt of I.


RX(1) OF 6 A + B ==> C...



A: CM 1




A: CM 2




B

(1) \longrightarrow



C: CM 1



C: CM 2

RX(1) RCT A 862543-53-1

STAGE(1)

RGT D 1333-74-0 H2
CAT 7440-05-3 Pd
SOL 7732-18-5 Water, 67-63-0 Me2CHOH
CON 4 hours, 75 - 80 deg C, 50 psi

STAGE(2)

RCT B 85943-26-6
SOL 67-63-0 Me2CHOH
CON 2 hours, 75 - 80 deg C

STAGE(3)

RGT D 1333-74-0 H2
CON SUBSTAGE(1) 30 - 40 deg C
SUBSTAGE(2) 3.5 hours, 75 - 80 deg C, 50 psi
SUBSTAGE(3) 10 hours, 25 - 30 deg C, 10 psi
SUBSTAGE(4) 11.5 hours, 75 - 80 deg C, 50 psi
SUBSTAGE(5) 10 hours, 25 - 30 deg C, 10 psi

SUBSTAGE(6) 3 hours, 75 - 80 deg C, 50 psi

PRO C 862543-52-0

REFERENCE COUNT: 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 7 CASREACT COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:

141:6864 CASREACT

TITLE:

Tritiation of nonpeptide substance P antagonist
CP-96,345 and its azido analogue. Synthetic and
characterization details

AUTHOR(S):

Egan, Judith A.; Filer, Crist N.

CORPORATE SOURCE:

PerkinElmer Life and Analytical Sciences, Inc.,
Boston, MA, 02118, USA

SOURCE:

Applied Radiation and Isotopes (2003), 59(5-6),
333-335

CODEN: ARISEF; ISSN: 0969-8043

PUBLISHER:

Elsevier Science B.V.


DOCUMENT TYPE:

Journal

LANGUAGE:


English

GI



AB CP-96,345 was the first nonpeptide antagonist discovered for the SP receptor and [3H] CP-96,345 was required to study the mechanism of receptor action. The radioligand I (R1 = T, R2 = H) was prepared at high specific activity by catalytic dehalogenation of a dibrominated precursor I (R1 = Br, R2 = H). The photoaffinity analog I (R1 = T, R2 = N3) was also prepared from precursor I (R1 = Br, R2 = NH2) using the same approach followed by diazotization and azidation with NaN3.


RX(1) OF 4 A ==> B



RX(1) RCT A 135007-76-0
 RGT C 10028-17-8 Tritium
 PRO B 135007-77-1
 CAT 7440-05-3 Pd
 SOL 64-17-5 EtOH
 CON 1 hour, room temperature


REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


ACCESSION NUMBER: 137:369932 CASREACT
 TITLE: Cooperative problem solving: investigation into the oxidative degradation of CJ-11,974-01 and [14C]CJ-11,974-01
 AUTHOR(S): Zandi, Kathleen S.; Huff, Barbara B.; Kamel, Amin; Larmann, John; Massefski, Walter W.; McCarthy, Keith E.; Miller, Sandra A.; Smith, Scott W.
 CORPORATE SOURCE: Radiochemical Synthesis, Pfizer Central Research, Groton, CT, 06340, USA
 SOURCE: Synthesis and Applications of Isotopically Labelled Compounds, Proceedings of the International Symposium, 7th, Dresden, Germany, June 18-22, 2000 (2001), Meeting Date 2000, 232-235. Editor(s): Pleiss, Ulrich; Voges, Rolf. John Wiley & Sons Ltd.: Chichester, UK.
 CODEN: 69CIJC; ISBN: 0-471-49501-8
 DOCUMENT TYPE: Conference
 LANGUAGE: English
 GI



AB Bulk CJ-11,974-01 (I) is stable as a drug substance but degrades over time in some solid dosage formulations. Minor impurities were identified as synthetic intermediates and a major degradant has a mol. weight of M+32 by mass spectral anal., suggesting the addition of two oxygen atoms. Using solution phase hydrogen/deuterium exchange and HPLC/ESI/MS/MS techniques, the degradation product was identified as the benzyl hydroperoxide derivative. The [14C]CJ-11,974-01 in ethanol solution is quite stable but is unstable as a solid, degrading to the same M+32 degradation product over a relatively short period of time. Storage of solid [14C]CJ-11,974-01 under inert atmospheric or at lower temps. did not considerably slow the degradation. The carbon-14 labeled degradant was isolated by normal and reverse phase chromatogs. and identified by NMR spectroscopy and MS as the iso-Pr peroxide.

RX(2) OF 6 ...C + E ==> F...





F
YIELD 88%

RX(2) RCT C 475146-68-0

STAGE(1)

RGT G 79-37-8 (COC1)2

SOL 75-09-2 CH2Cl2

STAGE(2)

RCT E 142035-23-2


PRO F 475146-69-1

NTE radiochem.

REFERENCE COUNT: 2


THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 134:266175 CASREACT
 TITLE: Synthesis and stability of substance P antagonists
 [14C]CJ-11,974-01 and [14C]CJ-11,972-01
 AUTHOR(S): Zandi, K. S.; Miller, S. A.; McCarthy, K. E.;
 Massefski, W. W.; Kamel, A.
 CORPORATE SOURCE: Radiochemical Synthesis, Pfizer Central Research,
 Groton, CT, 06340, USA
 SOURCE: Isotope Production and Applications in the 21st
 Century, Proceedings of the International Conference
 on Isotopes, 3rd, Vancouver, BC, Canada, Sept. 6-10,
 1999 (2000), Meeting Date 1999, 400-402. Editor(s):
 Stevenson, Nigel R. World Scientific Publishing Co.
 Pte. Ltd.: Singapore, Singapore.
 CODEN: 69ATWE
 DOCUMENT TYPE: Conference
 LANGUAGE: English
 GI



AB CJ-11,974-01 (I, R = CHMe2) and CJ-11,972-01 (I, R = CMe3) are structurally related substance P antagonists currently in development (-01 indicates the HCl salt). The synthesis of radiolabeled analogs was completed to aid in full ADME characterization. A straightforward route to both compds. was developed via directed lithiation/metal halogen exchange and carbonation. Conversion to the benzylic amine was accomplished by one of two methods. In the case of [14C]CJ-11,974-01, the carboxylic acid chloride was treated with a chiral amine followed by amide reduction, and for [14C]CJ-11,972-01, conversion to the aldehyde was followed by reductive amination. While both [14C]CJ-11,974-01 and [14C]CJ-11,972-01 are quite stable in solution, when stored as a solid, [14C]CJ-11,974-01 degrades to one major degradation product over a relatively short time period. The carbon-14 labeled degradation product was isolated from low specific activity material and identified by HPLC/MS/MS and NMR to be an iso-Pr peroxide. Studies were performed to identify the factors responsible for the oxidative degradation of [14C]CJ-11,974-01, which included salt form, storage conditions and salt formation solvent. Of all the variables studied over a three week period, only a change in the salt form prevented this oxidative degradation


RX(1) OF 2 A + B + C ==> D



A




B



C

(1) \longrightarrow



● x HCl

D

RX(1) RCT A 4132-48-3

STAGE(1)

RGT E 109-72-8 BuLi

SOL 109-99-9 THF

STAGE(2)

RCT B 51-90-1

STAGE(3)

RGT F 79-37-8 (COCl)₂

STAGE(4)

RCT C 142035-23-2

RGT G 121-44-8 Et₃N

STAGE(5)


RGT H 14044-65-6 BH₃-THF

PRO D 331676-67-6

ACCESSION NUMBER: 125:49301 CASREACT
 TITLE: Preparation of quinuclidine derivatives as substance P antagonists
 INVENTOR(S): Lowe, John Adams
 PATENT ASSIGNEE(S): Pfizer Inc., India
 SOURCE: Indian, 69 pp.
 CODEN: INXXAP
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 173570	A1	19940604	IN 1989-DE1094	19891123
PRIORITY APPLN. INFO.:			IN 1989-DE1094	19891123
OTHER SOURCE(S):			MARPAT 125:49301	

GI




AB Quinuclidine derivs. [I; Ar = thienyl, Ph, halophenyl; R = H, C1-4 alkyl; R1 = C5-7 cycloalkyl, norbornyl, pyrrolyl, 2,3-dihydrobenzofuranyl, (alkoxy)thienyl, (hydroxy)pyridyl, quinolinyl, indolyl, (alkoxy)naphthyl, biphenyl, 2,3-methylenedioxyphenyl, substituted Ph, etc.; R2 = branched alkyl or alkenyl, C5-7 cycloalkyl, furyl, thienyl, (substituted) Ph, phenylalkyl, C1-3 alkoxy, etc.] are prepared for use as substance P antagonists for treatment of gastrointestinal and central nervous (psychotic) disorders, inflammatory diseases, pain, and migraine. I are prepared by reduction of the corresponding quinuclidine imine or amide. Thus, 3-keto-2-benzhydrylquinuclidine condensed with cyclohexylmethylamine to form an imine, which was reduced with 9-borabicyclononane in THF to cis-3-(cyclohexylmethylamino)-2-benzhydrylquinuclidine.

RX(3) OF 42 ...M ==> N



M

(3) →



N

YIELD 46%

RX(3)	RCT	M	177746-08-6
	RGT	O	540-69-2 Ammonium formate
	PRO	N	160551-65-5
	CAT		7440-05-3 Pd
	SOL		64-17-5 EtOH

ACCESSION NUMBER:

122:9904 CASREACT

TITLE:

Synthesis of a benzo[b]-1,5-naphthyridine derivative as a potential constrained NK1 receptor antagonist
Viti, Giovanni; Giannotti, Danilo; Nannicini, Rossano; Balacco, Giuseppe; Pestellini, Vittorio

AUTHOR(S):

CORPORATE SOURCE:

Chem. Res. Dep., Firenze, 50131, Italy
Tetrahedron Letters (1994), 35(32), 5939-42

SOURCE:

CODEN: TELEAY; ISSN: 0040-4039


DOCUMENT TYPE:

Journal

LANGUAGE:

English


GI




I

AB A short synthesis of a cyclic constrained analog I of the potent Substance P antagonist (\pm)-CP-96345 is described. The key feature is the formation of the benzo[b]-1,5-naphthyridine system at the very last step of the synthesis through an intramol. arylation of an amine promoted by a strong base. If the tricyclic system was synthesized first, 2-methoxybenzylation of both the nitrogen atoms occurred.

RX(5) OF 9 ...O + R ==> A...



O



R

(5) \longrightarrow

ACCESSION NUMBER: 117:48289 CASREACT

TITLE: The discovery of
(2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine as a novel, nonpeptide substance P antagonist

AUTHOR(S): Lowe, John A., III; Drozda, Susan E.; Snider, R. Michael; Longo, Kelly P.; Zorn, Stevin H.; Morrone, Jean; Jackson, Elisa R.; McLean, Stafford; Bryce, Dianne K.; et al.


CORPORATE SOURCE: Cent. Res. Div., Pfizer, Inc., Groton, CT, 06340, USA
SOURCE: Journal of Medicinal Chemistry (1992), 35(14), 2591-600

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal


LANGUAGE: English

GI



AB The structure-activity relationship of a series of quinuclidines is described which culminated in the first potent, selective, nonpeptide substance P (SP) antagonist, (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine, (I; CP-96,345). I is a potent displacer of [3H]SP binding in human IM-9 cells and blocks SP-induced and capsaicin-induced plasma extravasation, as well as SP-induced salivation in the rat in vivo. I may both help to further the understanding of the interactions of small mols. with peptide receptors and serve to evaluate the therapeutic potential of a SP antagonist.

RX(1) OF 35 A + B ==> C...



RX(1) RCT A 6850-57-3, B 32531-66-1
PRO C 135095-42-0
SOL 108-88-3 PhMe, 109-99-9 THF

=> d his

(FILE 'HOME' ENTERED AT 14:55:22 ON 04 FEB 2009)

FILE 'REGISTRY' ENTERED AT 14:55:31 ON 04 FEB 2009

L1	STRUCTURE UPLOADED
L2	0 S L1 FULL
L3	STRUCTURE UPLOADED
L4	0 S L3 FULL
L5	STRUCTURE UPLOADED
L6	431 S L5 FULL
L7	STRUCTURE UPLOADED
L8	335 S L7 FULL

FILE 'CASREACT' ENTERED AT 15:03:47 ON 04 FEB 2009

L9	STRUCTURE UPLOADED
L10	7 S L9 FULL

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	160.56	909.10
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-5.46	-5.46

STN INTERNATIONAL LOGOFF AT 15:05:29 ON 04 FEB 2009